Stereotactic Body Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer
Keywords:
No KeywordAbstract
No Abstract
References
1. Hansen H. Introduction. In: Lung Cancer Therapy Annual, ed 6. Edited
by Hansen H. New York: Informa Health Care. 2009:1-6.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,
2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49.
3. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP,
Miettinen OS. Survival of patients with stage I lung cancer detected on
CT screening. N Engl J Med. 2006 Oct 26;355(17):1763-71.
4. Smolle-Juettner FM, Maier A, Lindenmann J, Matzi V, Neubock N.
Resection in stage I/II non-small cell lung cancer. Front Radiat Ther
Oncol. 2010;42:71-7.
5. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus
limited resection for T1 N0 non-small cell lung cancer. Lung Cancer
Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22.
6. Mountain CF. Prognostic implications of the International Staging System
for Lung Cancer. Semin Oncol. 1988 Jun;15(3):236-45.
7. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only
management of early stage, medically inoperable lung cancer: poor outcome.
Chest. 2002 Apr;121(4):1155-8.
8. Jensik RJ, Faber LP, Milloy FJ, Monson DO. Segmental resection for
lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg. 1973
Oct;66(4):563-72.
9. Sibley GS. Radiotherapy for patients with medically inoperable Stage I
nonsmall cell lung carcinoma: smaller volumes and higher doses--a review.
Cancer. 1998 Feb 1;82(3):433-8.
10. Dosoretz DE, Galmarini D, Rubenstein JH, Katin MJ, Blitzer PH, Salenius
SA, et al. Local control in medically inoperable lung cancer: an
analysis of its importance in outcome and factors determining the probability
of tumor eradication. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27
(3):507-16.
11. Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R. The role of radiotherapy
in treatment of stage I non-small cell lung cancer. Lung Cancer.
2003 Jul;41(1):1-11.
12. Dosoretz DE, Katin MJ, Blitzer PH, Rubenstein JH, Galmarini DH,
Garton GR, et al. Medically Inoperable Lung Carcinoma: The Role of
Radiation Therapy. Semin Radiat Oncol. 1996 Apr;6(2):98-104.
13. Kaskowitz L, Graham MV, Emami B, Halverson KJ, Rush C. Radiation
therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol
Biol Phys. 1993 Oct 20;27(3):517-23.
14. Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy
alone for medically inoperable stage I non-small-cell lung cancer:
the Duke experience. Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):149-
54.
15. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, et al.
A comparison of two stereotactic body radiation fractionation schedules
for medically inoperable stage I non-small cell lung cancer: the Cleveland
Clinic experience. J Thorac Oncol. 2009 Aug;4(8):976-82.
16. Fang LC, Komaki R, Allen P, Guerrero T, Mohan R, Cox JD. Comparison
of outcomes for patients with medically inoperable Stage I non-small-cell
lung cancer treated with two-dimensional vs. three-dimensional radio
therapy. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):108-16.
17. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T,
et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic
body radiotherapy in 4 fractions for primary lung cancer using a stereotactic
body frame. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31.
18. Liu H CB, Zhang J. Assessing respiration-induced tumor motion and
margin of internal target volume for image-guided radiotherapy of lung
cancers. Int J Radiat Oncol Biol Phys. 2005;63(Suppl 1):S30.
19. Ramsey CR, Scaperoth D, Arwood D, Oliver AL. Clinical efficacy of
respiratory gated conformal radiation therapy. Med Dosim. 1999 Summer;
24(2):115-9.
20. Rosenzweig KE, Hanley J, Mah D, Mageras G, Hunt M, Toner S, et al.
The deep inspiration breath-hold technique in the treatment of inoperable
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48
(1):81-7.
21. Sixel KE, Aznar MC, Ung YC. Deep inspiration breath hold to reduce
irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol
Phys. 2001 Jan 1;49(1):199-204.
22. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA,
et al. Impact of FDG-PET on radiation therapy volume delineation in
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 May 1;59
(1):78-86.
23. Krol AD, Aussems P, Noordijk EM, Hermans J, Leer JW. Local irradiation
alone for peripheral stage I lung cancer: could we omit the elective
regional nodal irradiation? Int J Radiat Oncol Biol Phys. 1996 Jan 15;34
(2):297-302.
24. Sulman E, Chang J, Liao Zea. Exclusion of elective nodal irradiation
does not decrease local regional control of non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 2005;63(Suppl 1):S226-227.
25. Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y,
et al. Evaluation of microscopic tumor extension in non-small-cell lung
cancer for three-dimensional conformal radiotherapy planning. Int J Radiat
Oncol Biol Phys. 2000 Nov 1;48(4):1015-24.
26. Chang J, Balter P, Liao Zea. Preliminary report of image-guided hypofractionated
stereotactic body radiotherapy to treat patients with medically
inoperable stage I or isolated peripheral lung recurrent non-smallcell
lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(3):S480.
27. Guckenberger M, Richter A, Wilbert J, et al. Cone-beam CT based image
guidance for hypofractionated radiotherapy of intrapulmonary lesionsevaluation
of benefits and limitations. Int J Radiat Oncol Biol Phys. 2006;
66(3 Suppl 1):S154.
28. David S E, Wallace A, Gerold B, Matthew G B, et al. Non-small cell
Lung cancer. National Comprehensive Cancer Network. 2010;v.2:29, 31-32.
29. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J,
et al. Excessive toxicity when treating central tumors in a phase II study
of stereotactic body radiation therapy for medically inoperable early-stage
lung cancer. J Clin Oncol. 2006 Oct 20;24(30):4833-9.
30. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson
MA, et al. Stereotactic body radiation therapy for early-stage nonsmall-
cell lung carcinoma: four-year results of a prospective phase II
study. Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82.
31. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al.
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I nonsmall
cell lung cancer: updated results of 257 patients in a Japanese multiinstitutional
study. J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100.
32. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. Computed
tomography-guided frameless stereotactic radiotherapy for stage I
non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol
Phys. 2001 Nov 1;51(3):666-70.
33. Thames HD Jr, Withers HR, Peters LJ, Fletcher GH. Changes in early
and late radiation responses with altered dose fractionation: implications
for dose-survival relationships. Int J Radiat Oncol Biol Phys. 1982 Feb;
8(2):219-26.
34. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al.
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall
cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese
multiinstitutional study. Cancer. 2004 Oct 1;101(7):1623-31.
35. Timmerman RD. An overview of hypofractionation and introduction to
this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008
Oct;18(4):215-22.
36. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore
MA, Lambin P. Comparison of the effectiveness of radiotherapy with
photons, protons and carbon-ions for non-small cell lung cancer: a metaanalysis.
Radiother Oncol. 2010 Apr;95(1):32-40.
37. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al.
Outcome in a prospective phase II trial of medically inoperable stage I
non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
J Clin Oncol. 2009 Jul 10;27(20):3290-6.
38. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S,
et al. Factors important for efficacy of stereotactic body radiotherapy of
medically inoperable stage I lung cancer. A retrospective analysis of
patients treated in the Nordic countries. Acta Oncol. 2006;45(7):787-95.
39. Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al.
Dose-response relationship for image-guided stereotactic body radiotherapy
of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat
Oncol Biol Phys. 2009 May 1;74(1):47-54.
40. Inoue T, Shimizu S, Onimaru R, Takeda A, Onishi H, Nagata Y, et al.
Clinical outcomes of stereotactic body radiotherapy for small lung lesions
clinically diagnosed as primary lung cancer on radiologic examination.
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):683-7.
41. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes
of risk-adapted fractionated stereotactic radiotherapy for stage I non-smallcell
lung cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92.
42. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, et al.
Extracranial stereotactic radioablation: results of a phase I study in medi
cally inoperable stage I non-small cell lung cancer. Chest. 2003 Nov;
124(5):1946-55.
43. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic
irradiation of lung tumors. Radiother Oncol. 2005 Oct;77(1):83-7.
44. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J,
et al. Stereotactic body radiation therapy for inoperable early stage lung
cancer. JAMA. 2010 Mar 17;303(11):1070-6.
45. Kimura T, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y,
et al. CT appearance of radiation injury of the lung and clinical symptoms
after stereotactic body radiation therapy (SBRT) for lung cancers: are
patients with pulmonary emphysema also candidates for SBRT for lung
cancers? Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):483-91.
46. Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H, et al.
Possible misinterpretation of demarcated solid patterns of radiation fibrosis
on CT scans as tumor recurrence in patients receiving hypofractionated
stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys.
2008 Mar 15;70(4):1057-65.
47. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K,
et al. Chest wall volume receiving >30 Gy predicts risk of severe pain
and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat
Oncol Biol Phys. 2010 Mar 1;76(3):796-801.
48. Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures
after hypofractionated stereotactic body radiation therapy of non-small
cell lung cancer: a dose- and volume-response analysis. Radiother Oncol.
2009 Jun;91(3):360-8.
49. Kawase T, Takeda A, Kunieda E, Kokubo M, Kamikubo Y, Ishibashi R,
et al. Extrapulmonary soft-tissue fibrosis resulting from hypofractionated
stereotactic body radiotherapy for pulmonary nodular lesions. Int J Radiat
Oncol Biol Phys. 2009 Jun 1;74(2):349-54.
50. Hoppe BS, Laser B, Kowalski AV, Fontenla SC, Pena-Greenberg E, Yorke
ED, et al. Acute skin toxicity following stereotactic body radiation therapy
for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol
Biol Phys. 2008 Dec 1;72(5):1283-6.
51. Forquer JA, Fakiris AJ, Timmerman RD, Lo SS, Perkins SM, McGarry
RC, et al. Brachial plexopathy from stereotactic body radiotherapy in
early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother
Oncol. 2009 Dec;93(3):408-13.
52. Greene F, Page D, Fleming I, Fritz A, eds. American Joint Committee
on Cancer (AJCC), Cancer Staging Manual 6th ed. New York: Springer;
2002.
53. Edge S, Byrd D, Compton C, Fritz A, eds. American Joint Committee
on Cancer (AJCC), Cancer Staging Manual. Philadelphia: Lippincott
Raven; 2010.
by Hansen H. New York: Informa Health Care. 2009:1-6.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,
2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49.
3. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP,
Miettinen OS. Survival of patients with stage I lung cancer detected on
CT screening. N Engl J Med. 2006 Oct 26;355(17):1763-71.
4. Smolle-Juettner FM, Maier A, Lindenmann J, Matzi V, Neubock N.
Resection in stage I/II non-small cell lung cancer. Front Radiat Ther
Oncol. 2010;42:71-7.
5. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus
limited resection for T1 N0 non-small cell lung cancer. Lung Cancer
Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22.
6. Mountain CF. Prognostic implications of the International Staging System
for Lung Cancer. Semin Oncol. 1988 Jun;15(3):236-45.
7. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only
management of early stage, medically inoperable lung cancer: poor outcome.
Chest. 2002 Apr;121(4):1155-8.
8. Jensik RJ, Faber LP, Milloy FJ, Monson DO. Segmental resection for
lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg. 1973
Oct;66(4):563-72.
9. Sibley GS. Radiotherapy for patients with medically inoperable Stage I
nonsmall cell lung carcinoma: smaller volumes and higher doses--a review.
Cancer. 1998 Feb 1;82(3):433-8.
10. Dosoretz DE, Galmarini D, Rubenstein JH, Katin MJ, Blitzer PH, Salenius
SA, et al. Local control in medically inoperable lung cancer: an
analysis of its importance in outcome and factors determining the probability
of tumor eradication. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27
(3):507-16.
11. Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R. The role of radiotherapy
in treatment of stage I non-small cell lung cancer. Lung Cancer.
2003 Jul;41(1):1-11.
12. Dosoretz DE, Katin MJ, Blitzer PH, Rubenstein JH, Galmarini DH,
Garton GR, et al. Medically Inoperable Lung Carcinoma: The Role of
Radiation Therapy. Semin Radiat Oncol. 1996 Apr;6(2):98-104.
13. Kaskowitz L, Graham MV, Emami B, Halverson KJ, Rush C. Radiation
therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol
Biol Phys. 1993 Oct 20;27(3):517-23.
14. Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy
alone for medically inoperable stage I non-small-cell lung cancer:
the Duke experience. Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):149-
54.
15. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, et al.
A comparison of two stereotactic body radiation fractionation schedules
for medically inoperable stage I non-small cell lung cancer: the Cleveland
Clinic experience. J Thorac Oncol. 2009 Aug;4(8):976-82.
16. Fang LC, Komaki R, Allen P, Guerrero T, Mohan R, Cox JD. Comparison
of outcomes for patients with medically inoperable Stage I non-small-cell
lung cancer treated with two-dimensional vs. three-dimensional radio
therapy. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):108-16.
17. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T,
et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic
body radiotherapy in 4 fractions for primary lung cancer using a stereotactic
body frame. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31.
18. Liu H CB, Zhang J. Assessing respiration-induced tumor motion and
margin of internal target volume for image-guided radiotherapy of lung
cancers. Int J Radiat Oncol Biol Phys. 2005;63(Suppl 1):S30.
19. Ramsey CR, Scaperoth D, Arwood D, Oliver AL. Clinical efficacy of
respiratory gated conformal radiation therapy. Med Dosim. 1999 Summer;
24(2):115-9.
20. Rosenzweig KE, Hanley J, Mah D, Mageras G, Hunt M, Toner S, et al.
The deep inspiration breath-hold technique in the treatment of inoperable
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48
(1):81-7.
21. Sixel KE, Aznar MC, Ung YC. Deep inspiration breath hold to reduce
irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol
Phys. 2001 Jan 1;49(1):199-204.
22. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA,
et al. Impact of FDG-PET on radiation therapy volume delineation in
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 May 1;59
(1):78-86.
23. Krol AD, Aussems P, Noordijk EM, Hermans J, Leer JW. Local irradiation
alone for peripheral stage I lung cancer: could we omit the elective
regional nodal irradiation? Int J Radiat Oncol Biol Phys. 1996 Jan 15;34
(2):297-302.
24. Sulman E, Chang J, Liao Zea. Exclusion of elective nodal irradiation
does not decrease local regional control of non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 2005;63(Suppl 1):S226-227.
25. Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y,
et al. Evaluation of microscopic tumor extension in non-small-cell lung
cancer for three-dimensional conformal radiotherapy planning. Int J Radiat
Oncol Biol Phys. 2000 Nov 1;48(4):1015-24.
26. Chang J, Balter P, Liao Zea. Preliminary report of image-guided hypofractionated
stereotactic body radiotherapy to treat patients with medically
inoperable stage I or isolated peripheral lung recurrent non-smallcell
lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(3):S480.
27. Guckenberger M, Richter A, Wilbert J, et al. Cone-beam CT based image
guidance for hypofractionated radiotherapy of intrapulmonary lesionsevaluation
of benefits and limitations. Int J Radiat Oncol Biol Phys. 2006;
66(3 Suppl 1):S154.
28. David S E, Wallace A, Gerold B, Matthew G B, et al. Non-small cell
Lung cancer. National Comprehensive Cancer Network. 2010;v.2:29, 31-32.
29. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J,
et al. Excessive toxicity when treating central tumors in a phase II study
of stereotactic body radiation therapy for medically inoperable early-stage
lung cancer. J Clin Oncol. 2006 Oct 20;24(30):4833-9.
30. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson
MA, et al. Stereotactic body radiation therapy for early-stage nonsmall-
cell lung carcinoma: four-year results of a prospective phase II
study. Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82.
31. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al.
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I nonsmall
cell lung cancer: updated results of 257 patients in a Japanese multiinstitutional
study. J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100.
32. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. Computed
tomography-guided frameless stereotactic radiotherapy for stage I
non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol
Phys. 2001 Nov 1;51(3):666-70.
33. Thames HD Jr, Withers HR, Peters LJ, Fletcher GH. Changes in early
and late radiation responses with altered dose fractionation: implications
for dose-survival relationships. Int J Radiat Oncol Biol Phys. 1982 Feb;
8(2):219-26.
34. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al.
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall
cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese
multiinstitutional study. Cancer. 2004 Oct 1;101(7):1623-31.
35. Timmerman RD. An overview of hypofractionation and introduction to
this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008
Oct;18(4):215-22.
36. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore
MA, Lambin P. Comparison of the effectiveness of radiotherapy with
photons, protons and carbon-ions for non-small cell lung cancer: a metaanalysis.
Radiother Oncol. 2010 Apr;95(1):32-40.
37. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al.
Outcome in a prospective phase II trial of medically inoperable stage I
non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
J Clin Oncol. 2009 Jul 10;27(20):3290-6.
38. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S,
et al. Factors important for efficacy of stereotactic body radiotherapy of
medically inoperable stage I lung cancer. A retrospective analysis of
patients treated in the Nordic countries. Acta Oncol. 2006;45(7):787-95.
39. Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al.
Dose-response relationship for image-guided stereotactic body radiotherapy
of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat
Oncol Biol Phys. 2009 May 1;74(1):47-54.
40. Inoue T, Shimizu S, Onimaru R, Takeda A, Onishi H, Nagata Y, et al.
Clinical outcomes of stereotactic body radiotherapy for small lung lesions
clinically diagnosed as primary lung cancer on radiologic examination.
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):683-7.
41. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes
of risk-adapted fractionated stereotactic radiotherapy for stage I non-smallcell
lung cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92.
42. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, et al.
Extracranial stereotactic radioablation: results of a phase I study in medi
cally inoperable stage I non-small cell lung cancer. Chest. 2003 Nov;
124(5):1946-55.
43. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic
irradiation of lung tumors. Radiother Oncol. 2005 Oct;77(1):83-7.
44. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J,
et al. Stereotactic body radiation therapy for inoperable early stage lung
cancer. JAMA. 2010 Mar 17;303(11):1070-6.
45. Kimura T, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y,
et al. CT appearance of radiation injury of the lung and clinical symptoms
after stereotactic body radiation therapy (SBRT) for lung cancers: are
patients with pulmonary emphysema also candidates for SBRT for lung
cancers? Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):483-91.
46. Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H, et al.
Possible misinterpretation of demarcated solid patterns of radiation fibrosis
on CT scans as tumor recurrence in patients receiving hypofractionated
stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys.
2008 Mar 15;70(4):1057-65.
47. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K,
et al. Chest wall volume receiving >30 Gy predicts risk of severe pain
and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat
Oncol Biol Phys. 2010 Mar 1;76(3):796-801.
48. Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures
after hypofractionated stereotactic body radiation therapy of non-small
cell lung cancer: a dose- and volume-response analysis. Radiother Oncol.
2009 Jun;91(3):360-8.
49. Kawase T, Takeda A, Kunieda E, Kokubo M, Kamikubo Y, Ishibashi R,
et al. Extrapulmonary soft-tissue fibrosis resulting from hypofractionated
stereotactic body radiotherapy for pulmonary nodular lesions. Int J Radiat
Oncol Biol Phys. 2009 Jun 1;74(2):349-54.
50. Hoppe BS, Laser B, Kowalski AV, Fontenla SC, Pena-Greenberg E, Yorke
ED, et al. Acute skin toxicity following stereotactic body radiation therapy
for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol
Biol Phys. 2008 Dec 1;72(5):1283-6.
51. Forquer JA, Fakiris AJ, Timmerman RD, Lo SS, Perkins SM, McGarry
RC, et al. Brachial plexopathy from stereotactic body radiotherapy in
early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother
Oncol. 2009 Dec;93(3):408-13.
52. Greene F, Page D, Fleming I, Fritz A, eds. American Joint Committee
on Cancer (AJCC), Cancer Staging Manual 6th ed. New York: Springer;
2002.
53. Edge S, Byrd D, Compton C, Fritz A, eds. American Joint Committee
on Cancer (AJCC), Cancer Staging Manual. Philadelphia: Lippincott
Raven; 2010.
Downloads
Published
03-04-2020
How to Cite
Mahasittiwat, P. ., Ieumwananonthachai, N., Petsuksiri, J. ., & Pataranutraporn, P. . (2020). Stereotactic Body Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer. Siriraj Medical Journal, 63(2), 68–72. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/240912
Issue
Section
Review Article
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
